SKI: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

Target Name: SKI

NCBI ID: G6497

SKI: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

SKI (Avian sarcoma viral oncogene homolog) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new treatments.

SKI is a member of the Avian sarcoma viral oncogene homolog (ASVH) family, which is known for their ability to cause cancer in birds. These viruses have a unique mechanism of replication, which involves the transformation of host cells into cancerous cells. The ASVH family has also been linked to the development of various cancers, including breast, ovarian, and prostate cancer.

SKI is a non-coding RNA molecule that has been shown to play a role in the replication of ASVH viruses. It is a key regulator of the virus's replication and has been shown to interact with several host cell proteins. SKI has been shown to regulate the activity of the viral replication machinery, which is responsible for copying the viral genome into new host cells.

SKI has also been shown to play a role in the regulation of gene expression in host cells. It has been shown to interact with several host cell proteins, including the transcription factor ASXL1. This interaction between SKI and ASXL1 has been shown to regulate the expression of genes involved in cell growth, differentiation, and apoptosis.

SKI has also been shown to be involved in the development of cancer. Studies have shown that SKI is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development of cancer.

In addition to its role in cancer, SKI has also been shown to be involved in several other diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. It has also been shown to be involved in the regulation of inflammation, which is a critical part of the immune system.

SKI is a small molecule that can be easily synthesized and tested for as a drug target or biomarker. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new treatments for a variety of diseases.

SKI has been shown to be involved in the regulation of several host cell proteins, including the transcription factor ASXL1. This interaction between SKI and ASXL1 has been shown to regulate the expression of genes involved in cell growth, differentiation, and apoptosis.

SKI has also been shown to be involved in the development of cancer. Studies have shown that SKI is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development of cancer.

In addition to its role in cancer, SKI has also been shown to be involved in several other diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. It has also been shown to be involved in the regulation of inflammation, which is a critical part of the immune system.

SKI is a small molecule that can be easily synthesized and tested for as a drug target or biomarker. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new treatments for a variety of diseases. Further studies are needed to fully understand the role of SKI in disease and to develop new treatments based on its unique properties.

Protein Name: SKI Proto-oncogene

Functions: May play a role in terminal differentiation of skeletal muscle cells but not in the determination of cells to the myogenic lineage. Functions as a repressor of TGF-beta signaling

More Common Targets